Amelia Green
Lead/Senior Researcher
Dr Amelia Green leads the Research Software Innovation Team at the Bennett Institute for Applied Data Science, where her work sits at the intersection of research and software. She leads a multidisciplinary team focused on rapid experimentation: working closely with researchers to identify problems, test new ideas, and develop practical tools and approaches that make research faster, easier and more reproducible.
Amelia has over a decade of research experience and has worked extensively with large-scale, routinely collected health data. Much of her recent work has been within OpenSAFELY, where she has contributed to a wide range of research addressing clinical and public health questions. Her work has contributed to evidence informing clinical guidance, health policy and healthcare delivery in the UK and internationally.
Her research interests span statistical modelling, prediction and inference, with a particular interest in Bayesian methods and their application to complex real-world problems. She has worked across pharmacoepidemiology, public health and applied data science, and has contributed to more than 60 peer-reviewed publications.
Amelia holds a PhD in statistics and pharmacoepidemiology, an MSc in Mathematical Science, and a BSc in Mathematics and Sports Science. Her multidisciplinary background informs her approach to data science, combining rigorous quantitative research with the development of practical software and tools that enable researchers to work more effectively.
Papers by Amelia Green
- Impact of COVID-19 on recorded blood pressure screening and hypertension management in England
- Therapeutics Dataset from COVID-19 Medicine Delivery Units in England
- The safety of antivirals and neutralising monoclonal antibodies used in prehospital treatment of Covid-19
- OpenSAFELY: Effectiveness of COVID-19 vaccination in children and adolescents
- Comparative safety and effectiveness of Pfizer BA.4-5 versus Sanofi during the spring 2023 COVID-19 booster vaccination programme in England
- OpenSAFELY: a platform for analysing electronic health records designed for reproducible research
- Impact of the COVID-19 pandemic on antipsychotic prescribing in individuals with autism, dementia, learning disability, serious mental illness or living in a care home
- Eleven key measures for monitoring general practice clinical activity during COVID-19
- Changes in medication safety indicators in England throughout the covid-19 pandemic using OpenSAFELY
- Effectiveness of Sotrovimab and Molnupiravir in community settings in England across the Omicron BA.1 and BA.2 sublineages
- Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data
- Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings
- Factors associated with COVID-19 vaccine uptake in people with kidney disease
- Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community
- Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose
- Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England
- Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England
- Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies
- Safety of COVID-19 vaccination and acute neurological events
- Potentially inappropriate prescribing of DOACs to people with mechanical heart valves
- Mortality among Care Home Residents in England during the first and second waves of the COVID-19 pandemic
- Trends and clinical characteristics of COVID-19 vaccine recipients